China Medical System Holdings Limited (CHSYF)
- Previous Close
0.9313 - Open
0.9307 - Bid --
- Ask --
- Day's Range
0.9307 - 0.9307 - 52 Week Range
0.9307 - 1.6000 - Volume
5,110 - Avg. Volume
173 - Market Cap (intraday)
2.27B - Beta (5Y Monthly) 0.83
- PE Ratio (TTM)
6.65 - EPS (TTM)
0.1400 - Earnings Date Aug 26, 2024 - Aug 30, 2024
- Forward Dividend & Yield 0.05 (5.88%)
- Ex-Dividend Date May 13, 2024
- 1y Target Est
--
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. Its products include VALTOCO, a diazepam nasal spray to treat seizure clusters; Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu to treat acute heart failure; Deanxit for mild-to-moderate depression, anxiety, and psychosomatic affections; METOJECT, a methotrexate injection for recalcitrant disabling psoriasis; and Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis. The company also offers Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; ILUMETRI, a tildrakizumab injection to treat moderate-tosevere plaque psoriasis; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. In addition, it provides Aethoxysklerol for sclerotherapy of different varicose veins; Heling Soothing product for skin soothing; Vmonalisa for mid to deep dermal implantation; Neauvia Hyaluronic Acid series; EyeOP1 to treat glaucoma; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; MOVICOL for treating chronic constipation and faecal impaction; and MeteoSpasmyl to treat gastrointestinal flatulence and pain. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.
web.cms.net.cn/zh/home/5,701
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: CHSYF
Performance Overview: CHSYF
Trailing total returns as of 6/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CHSYF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CHSYF
Valuation Measures
Market Cap
2.06B
Enterprise Value
1.38B
Trailing P/E
6.77
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.03
Price/Book (mrq)
1.04
Enterprise Value/Revenue
1.22
Enterprise Value/EBITDA
3.12
Financial Highlights
Profitability and Income Statement
Profit Margin
29.96%
Return on Assets (ttm)
9.56%
Return on Equity (ttm)
15.74%
Revenue (ttm)
8.01B
Net Income Avi to Common (ttm)
2.4B
Diluted EPS (ttm)
0.1400
Balance Sheet and Cash Flow
Total Cash (mrq)
6.14B
Total Debt/Equity (mrq)
8.48%
Levered Free Cash Flow (ttm)
1.55B